Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel
NASDAQ:CRBU

Caribou Biosciences Q4 2024 Earnings Report

Caribou Biosciences logo
$1.95 +0.02 (+1.04%)
Closing price 05/6/2026 04:00 PM Eastern
Extended Trading
$1.94 -0.01 (-0.56%)
As of 05/6/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Caribou Biosciences EPS Results

Actual EPS
-$0.39
Consensus EPS
-$0.40
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Caribou Biosciences Revenue Results

Actual Revenue
$2.08 million
Expected Revenue
$2.11 million
Beat/Miss
Missed by -$29.00 thousand
YoY Revenue Growth
N/A

Caribou Biosciences Announcement Details

Quarter
Q4 2024
Date
3/10/2025
Time
Before Market Opens
Conference Call Date
Monday, March 10, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Caribou Biosciences' Q1 2026 earnings is estimated for Thursday, May 14, 2026, based on past reporting schedules, with a conference call scheduled on Friday, May 15, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Caribou Biosciences' Q4 2024 ReportReport
Caribou Biosciences' Q4 2024 Annual reportAnnual report
(10-K)

Caribou Biosciences Earnings Headlines

Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference
May 5 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3288251/0/en/caribou-biosciences-to-participate-in-the-bofa-securities-2026-health-care-conference.html
Caribou Biosciences (CRBU) price target decreased by 22.79% to 8.92
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/caribou-biosciences-crbu-price-target-decreased-by-22-79-to-8-92/ar-AA21WJ4a
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
 |  American Alternative (Ad)
Caribou rises on FDA RMAT designation for CAR-T therapy
April 1, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4570660-caribou-rises-fda-rmat-designation
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
March 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/31/3265437/0/en/caribou-biosciences-announces-the-fda-granted-regenerative-medicine-advanced-therapy-rmat-designation-to-cb-011-an-allogeneic-anti-bcma-car-t-cell-therapy.html
Leerink Partners Remains a Buy on Caribou Biosciences (CRBU)
March 11, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CRBU/pressreleases/623687/leerink-partners-remains-a-buy-on-caribou-biosciences-crbu/
See More Caribou Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Caribou Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Caribou Biosciences and other key companies, straight to your email.

About Caribou Biosciences

Caribou Biosciences (NASDAQ:CRBU) is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology. The company holds licenses to foundational CRISPR intellectual property from the University of California, enabling continuous innovation in genome engineering. Since completing its initial public offering in August 2021, Caribou has focused on progressing its clinical pipeline and expanding manufacturing capabilities to support its growing roster of investigational therapies.

Caribou’s leadership team combines deep expertise in molecular biology, clinical development and manufacturing scale-up, supported by an advisory board that includes leading figures in biotechnology and medicine. The company has established strategic collaborations with pharmaceutical and academic partners to advance its research programs and accelerate clinical translation. Caribou continues to conduct trials across multiple regions, aiming to bring its next-generation cell therapies and in vivo gene-editing treatments to patients worldwide.

View Caribou Biosciences Profile
Earnings Tools